NEW YORK, July 28, 2015 /PRNewswire/ -- Attorney
Advertising -- Bronstein, Gewirtz & Grossman, LLC is
investigating potential claims on behalf of purchasers of the
securities of Biogen, Inc. ("Biogen" or the "Company") (NasdaqGS:
BIIB -News). Such investors are advised to contact
Peretz Bronstein or his investor
relations coordinator Eitan Kimelman
at info@bgandg.com or 212-697-6484.
The investigation concerns whether Biogen and certain of its
officers and/or directors have violated Sections 10(b) and 20(a) of
the Securities Exchange Act of 1934.
On July 24, 2015, pre-market,
Biogen reported Q2 2015 results and updated its full-year financial
guidance from 14-16% to 6-8% above 2014 revenues. The Company also
announced that sales of the company's multiple-sclerosis drug
tecfidera have slowed on safety concerns following last year's
report of the death of a tecfidera patient.
On this news, Biogen shares have dropped as much as $74.34, or 19.31%, during intraday trading on
July 24, 2015.
If you are aware of any facts relating to this investigation, or
purchased shares of Biogen, you can assist this investigation by
contacting Peretz Bronstein or his
Investor Relations Coordinator Eitan
Kimelman of Bronstein, Gewirtz & Grossman, LLC at
212-697-6484 or via email info@bgandg.com. Those who inquire
by e-mail are encouraged to include their mailing address, email
and telephone number.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation
boutique. Our primary expertise is the aggressive pursuit of
litigation claims on behalf of our clients. In addition to
representing institutions and other investor plaintiffs in class
action security litigation, the firm's expertise includes general
corporate and commercial litigation, as well as securities
arbitration. Attorney advertising. Prior results do not
guarantee similar outcomes.
Contact:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Eitan Kimelman 212-697-6484
info@bgandg.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/shareholder-alert-bronstein-gewirtz--grossman-llc-announces-investigation-of-biogen-inc-300119669.html
SOURCE Bronstein, Gewirtz & Grossman, LLC